Neurology Solutions

View tests

The growing burden of neurological disease

Nearly 100 million Americans suffer from neurological diseases, including cognitive impairment, Alzheimer’s disease and other dementias, epilepsy, multiple sclerosis, and Parkinson’s disease.1 Prevalent among the elderly, these conditions will become increasingly common—and costly—as the number of US adults aged 65 or older more than doubles by 2030.2

The growing burden of neurological disease

  1. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action. Ann Neurol. 2017;81(4):479-484.
  2. Centers for Disease Control and Prevention. General information about the older adult population. Available at

Quest offers clinical insights for patients with neurological symptoms in all stages of life

neurological symptoms
  • Medical Expertise
  • Comprehensive Testing

Quest medical experts take you beyond the results

Our neurology diagnostics lead the way with more than 30 years of experience and a broad offering across the continuum of care.

Pre- or post-testing, Quest’s board-certified geneticists, researchers, and doctors:

  • Are easily accessible to assist clinicians.
  • Actively collaborate with leading academic institutions and government agencies to advance diagnostic technology.
  • Work closely with external thought leaders to pave new ground in diagnostic fields related to neurological conditions such as epilepsy, dementia, Charcot-Marie-Tooth disease (CMT), and Alzheimer’s disease.
  • Contribute to clinical evidence, publishing nearly 100 papers annually. Leverage the evidence base of these peer-reviewed publications, found here:

500+ tests for neurological diagnosis and treatment

Our suite of online research-based resources helps to guide test selection from our 
500+ immunoassays and genetic tests including biochemical genetics, cytogenetics, molecular genetics, and immunology assays for disorders both common and rare.

Over 40,000 pathogenicity assessments on 25,938 unique variants have been successfully performed to date to support a wide range of subspecialties including:

  • Neonatal disorders
  • Epilepsy
  • Neurodevelopmental disabilities
  • Neuromuscular disease
  • Multiple sclerosis
  • Cognitive impairment
  • Dementia
  • Movement disorders
  • and more

With an array of innovative neurological disease solutions that spans subspecialties, we make advanced neurology testing more accessible and actionable to help improve patient outcomes and reduce costs.

A few areas of focus include:

  • Innovative genetic testing improves diagnosis and treatment

    Quest designs tests for neurological disorders according to practice parameters, extensive literature review, and clinical evidence.

    For example, tests available through Quest and Athena Diagnostics include:

    • Exome sequencing by Quest Exome with CNV Evaluation helps to improve disease diagnosis, monitoring, and treatment of rare neurological disorders for which no diagnostic tests exist, targeted testing is impractical, or definitive tests are unavailable or non-informative.
    • Epilepsy Advanced Sequencing and CNV Evaluation ensures that each of 234 epilepsy genes are assessed to increase diagnostic accuracy and minimize the likelihood of a variant of unknown significance.
    • The NewbornDx™ Advanced Sequencing Evaluation provides the clinician with a single test that gives an accurate and timely molecular profile on 1,722 relevant newborn disease genes.
    • ADmark® Alzheimer’s Evaluation is performed together with CSF biomarkers and ApoE genotyping to improve test specificity and accuracy.
    • Neuromuscular Panels can assist in phenotype-based evaluation that enables earlier diagnosis.
    • The Hereditary Neuropathy Panel provides meaningful interpretation of CMT subtype.
    • Ataxia and HSP Panels offer phenotype-guided testing for hereditary ataxias and hereditary spastic paraplegia.

    Quest’s lab-based genetic counselors assist in test selection, results interpretation, and care plan development, leading to optimal utilization of genetic testing, significant cost savings, and insights to improve health outcomes.1


    genetic conditions can be tested for with genetic and genomic testing1

    Up to 30%

    of genetic tests are ordered incorrectly1

    1. Riley JD, Procop GW, Kottke-Marchant K, et al. improving molecular genetic test utilization through order restriction, test review, and guidance. J Mol Diagn. 2015;7(3):225-229.
    Read more …
  • Supporting precision health through pharmacogenomics

    Our Pharmacogenomics (PGx) Panel identifies DNA variations to help physicians gain insight into a patient’s potential response to medications and optimize their treatment considerations and outcomes.

    The PGx Panel is designed to analyze certain genetic changes or variations which can impact how patients 
will metabolize, absorb, or respond to a particular medication.

    For example, available estimates suggest relatively low rates of response (~30%1) to major drugs among patients with Alzheimer’s disease.

    Supporting precision health through pharmacogenomics

    Quest Diagnostics offers one of the most comprehensive pharmacogenomic test panels in order to help gain insights into a patient's genetic profile. It tests for changes in over 40 genes to help you anticipate possible adverse reactions and positive drug response.

    The use of data from pharmacogenomic testing can advance clinical outcomes, positively affect quality metrics, and improve financials for health systems by:

    • Maximizing drug effectiveness
    • Reducing adverse events
    • Minimizing gaps in care

    Realizing the Value of Pharmacogenomic Testing

    The implementation of PGx testing by health systems may help improve patient outcomes while reducing healthcare costs.

    1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7:201-204.
    2. US Food & Drug Administration 2018.
    3. Office of Disease Prevention and Health Promotion 2017. ED, emergency department.
    Read more …
  • Early detection of autoimmune neurological disorders can make a difference in patient outcomes

    Clinical neuroimmunology testing is a rapidly growing field driven by ongoing discovery of new neural autoantibodies. It is important to test for these antibodies as many are associated with treatable neurological diseases. Likewise, testing can be useful to exclude an immunological disorder that may be responsible for a patient’s neurological symptoms.

    Clinical neuroimmunology testing can identify many difficult-to-diagnose autoimmune neurological disorders including:

    Movement disorders
    Autoimmune ataxia, epilepsy, chorea
    Neuromuscular disorders
    Myasthenia gravis, Lambert-Eaton
    Paraneoplastic neurological syndrome (PNS)
    Brain function disorders
    Autoimmune dementia, encephalopathy
    Multiple sclerosis (MS), neuromyelitis optica (NMO)
    Peripheral nervous system (PNS) disorder
    Guillain-Barré syndrome (GBS), peripheral and sensory neuropathies

    Neuroimmunology Testing Services.

    Learn how Quest Diagnostics can be your source for neuroimmunological testing with expanded offerings for several autoimmune neurological disorders.

    Read more …
Take action

Contact us to see how Quest neurology solutions can benefit your health system and patients.

Contact us